• 1
    Wilson RA. Feminine forever. New York: M. Evans/J.B. Lippincott, 1966.
  • 2
    Bakken K, Eggen AE, Lund E. Side effects of hormone replacement therapy and influence on pattern of use among women 45–64 years. The Norwegian Women and Cancer (NOWAC) study 1997. Acta Obstet Gynecol Scand, 2004; 83: in press.
  • 3
    Grady D, Rubin SM, Petitti DB, Fox CS, Black D, Ettinger B, Ernster VL, Cummings SR. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992; 117: 101637.
  • 4
    Michaelsson K, Baron JA, Farahmand BY, Johnell O, Magnusson C, Persson PG, Persson I, Ljunghall S. Hormone replacement therapy and risk of hip fracture: population based case-control study. The Swedish Hip Fracture Study Group. BMJ 1998; 316: 18586.
  • 5
    Mosca L. The role of hormone replacement therapy in the prevention of postmenopausal heart disease. Arch Intern Med 2000; 160: 226372.
  • 6
    LeBlanc ES, Janowsky J, Chan BK, Nelson HD. Hormone replacement therapy and cognition: systematic review and meta-analysis. JAMA 2001; 285: 148999.
  • 7
    Lindsay R. Hormone replacement therapy for prevention and treatment of osteoporosis. Am J Med 1993; 95: 37S9S.
  • 8
    Haskell SG, Richardson ED, Horwitz RI. The effect of estrogen replacement therapy on cognitive function in women: a critical review of the literature. J Clin Epidemiol 1997; 50: 124964.
  • 9
    Paganini-Hill A. Estrogen replacement therapy and Alzheimer's disease. Br J Obstet Gynaecol 1996; 103 Suppl 13: 806.
  • 10
    WHO. Research on the menopause in the 1990s. Report of a WHO scientific group. Geneva: WHO, 1996.
  • 11
    Adami H-O, Hunter D, Trichopoulos D. Textbook of cancer epidemiology. Oxford: Oxford University Press, 2002.
  • 12
    Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997; 350: 104759.
  • 13
    Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 32133.
  • 14
    Beral V. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003; 362: 41927.
  • 15
    Bakken K, Eggen AE, Lund E. Hormone replacement therapy in Norwegian women, 1996–1997. Maturitas 2001; 40: 13141.
  • 16
    RønningM, ed. Drug consumption in Norway 1998–2002. Oslo: Norwegian Institute of Public Health, 2003.
  • 17
    Lund E, Kumle M, Braaten T, Hjartaker A, Bakken K, Eggen E, Gram IT. External validity in a population-based national prospective study—the Norwegian Women and Cancer Study (NOWAC). Cancer Causes Control 2003; 14: 10018.
  • 18
    Chlebowski RT, Hendrix SL, Langer RD, Stefanick ML, Gass M, Lane D, Rodabough RJ, Gilligan MA, Cyr MG, Thomson CA, KHandekar J, Petrovich H, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA 2003; 289: 324353.
  • 19
    Greendale GA, Reboussin BA, Sie A, Singh HR, Olson LK, Gatewood O, Bassett LV, Wasilauskas C, Bush T, Barrett-Connor E. Effects of estrogen and estrogen–progestin on mammographic parenchymal density. Postmenopausal Estrogen/Progestin Interventions (PEPI) Investigators. Ann Intern Med 1999; 130: 2629.
  • 20
    Colditz GA, Hankinson SE, Hunter DJ, Willett WC, Manson JE, Stampfer MJ, Hennekens C, Rosnes B, Speizer FE. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995; 332: 158993.
  • 21
    Ross RK, Paganini-Hill A, Wan PC, Pike MC. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst 2000; 92: 32832.
  • 22
    Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover R. Menopausal estrogen and estrogen–progestin replacement therapy and breast cancer risk. JAMA 2000; 283: 48591.
  • 23
    Eden J. Progestins and breast cancer. Am J Obstet Gynecol 2003; 188: 112331.
  • 24
    Magnusson C, Baron JA, Correia N, Bergstrom R, Adami HO, Persson I. Breast-cancer risk following long-term estrogen- and estrogen–progestin-replacement therapy. Int J Cancer 1999; 81: 33944.
  • 25
    Weiderpass E, Baron JA, Adami HO, Magnusson C, Lindgren A, Bergstrom R, Correia N, Persson I. Low-potency estrogen and risk of endometrial cancer: a case-control study. Lancet 1999; 353: 18248.
  • 26
    Garg PP, Kerlikowske K, Subak L, Grady D. Hormone replacement therapy and the risk of epithelial ovarian carcinoma: a meta-analysis. Obstet Gynecol 1998; 92: 4729.
  • 27
    Persson I, Bergkvist L, Adami HO. Reliability of women's histories of climacteric estrogen treatment assessed by prescription forms. Int J Epidemiol 1987; 16: 2228.